Fair Value Measurements (Tables)

6 Months Ended

Dec. 31, 2016

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Schedule Of Fair Value Hierarchy, Assets (Liabilities) Carried At Fair Value

(in millions)	Level 1		Level 2			Level 3			Total
Contingent consideration	$	—	$	—		$	(5.2	)	$	(5.2	)
Interest rate derivative instruments	—		(1.3		)	—			(1.3		)
Foreign currency exchange contracts	—		(5.3		)	—			(5.3		)
Total	$	—	$	(6.6	)	$	(5.2	)	$	(11.8	)

(in millions)	Level 1		Level 2			Level 3			Total
Contingent consideration	$	—	$	—		$	(14.0	)	$	(14.0	)
Forward share repurchase contract	—		—			19.7			19.7
Interest rate derivative instruments	—		0.5			—			0.5
Foreign currency exchange contracts	—		(5.3		)	—			(5.3		)
Total	$	—	$	(4.8	)	$	5.7		$	0.9

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]

The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:

	Health Advances	ExecuPharm
Unobservable Input	Range	Range
Risk free rate	1.3%	0.7%
Revenue volatility	26%	29%
Projected period of payment	Approximately 2 years	Approximately 2 years

The recurring Level 3 fair value measurements of our forward share repurchase contract asset include the following significant unobservable inputs:

	Forward Share
Unobservable Input	Repurchase Contract
Risk free rate	0.6%
Share price volatility	37.5
Contract term	0.4 years

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table provides a summary of the change in our valuation of the fair value of the forward share repurchase contract asset, which was determined by Level 3 inputs:

(in millions)
Balance at June 30, 2016	$	—
Additions of forward share repurchase contract	40.0
Change in fair value of forward share repurchase contract	(20.3		)
Balance at December 31, 2016	$	19.7

The following table provides a summary of the change in our valuation of the fair value of the contingent consideration liability, which was determined by Level 3 inputs:

(in millions)
Balance at June 30, 2016	$	5.2
Additions of contingent consideration due to ExecuPharm acquistion	9.4
Change in fair value of contingent consideration for Health Advances	(0.6		)
Balance at December 31, 2016	$	14.0